Broadcast

e-SPACE CRM 2025 – Day Two

Nisha Bansal, Antonio Ceriello, David Wheeler, et al

Broadcast

e-SPACE CRM 2025 – Day One

Nisha Bansal, Antonio Ceriello, David Wheeler, et al

Broadcast

Assessing the Shift Towards Personalised Medicine – Part 1

Jordana B Cohen, Kazem Rahimi

Broadcast

e-SPACE CRM 2024 - Day 2

Antonio Ceriello, Ileana L Piña, Gianluigi Savarese, et al

Broadcast

e-SPACE CRM 2024 - Day 1

Antonio Ceriello, Ileana L Piña, Gianluigi Savarese, et al

Broadcast

Assessing the Shift Towards Personalised Medicine – Part 1

Jordana B Cohen, Kazem Rahimi

Broadcast

e-SPACE CRM 2023 – Day One

Stefan Anker, Javed Butler, Antonio Ceriello, et al

About

Hypertension is the most common modifiable risk factor for cardiovascular disease and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and prevents cardiovascular disease outcomes.

Most hypertensive patients will need a combination of antihypertensive agents to achieve the therapeutic goals. Recent guidelines recommend initiating treatment with two drugs in those patients with a systolic blood pressure >20 mmHg and/or a diastolic blood pressure >10 mmHg above the goals, and in those patients with high cardiovascular risk. In addition, approximately 25% of patients will require three antihypertensive agents to achieve the therapeutic targets.

Articles

Link Between NAFLD/NASH and Cardiometabolic Syndrome

Published:

09 May 2024

Citation:

European Cardiology Review 2024;19:e03.

Cardiometabolic Risk Factors and COVID-19 in the Asia-Pacific Region

Published:

23 June 2023

Citation:

Journal of Asian Pacific Society of Cardiology 2023;2:e22.

APSC Consensus on OSA in CVD Patients

Published:

20 June 2022

Citation:

European Cardiology Review 2022;17:e16.